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Abstract
Thomas H. Auriemma
A DIGITAL APPLICATION TO ASSESS FOR NEUROCOGNITIVE DISABILITIES
2021-2022
Ganesh Baliga, Ph.D.
Master of Science in Computer Science

Neuropsychological assessments designed to identify neurodegenerative diseases
such as dementia rely on pen-and-paper tests administered by a trained medical practitioner
such as a neuropsychologist. When digitally administered, these assessments can provide
traditional test scoring metrics as well as many previously unobtainable time-based
parameters, such as inter-response latency. Recent research has demonstrated that these
digital assessments are able to identify cognitive impairments earlier that their traditional
counterparts. The current research features data collected on fifty-one patients using an
iPad app for the Philadelphia Pointing Span Test (PPST), a test designed to measure
executive abilities. These patients were also assessed using the standard Montreal
Cognitive Assessment (MoCA) test which provides neuropsychological indices measuring
executive, language, and memory abilities. Our analysis shows correlations between PPST
recall scores and MoCA’s executive assessment. Additionally, PPST latencies correlate
with patient cardiovascular risk.
In summary, the PPST appears to provide an effective assessment of executive
abilities and could be a parsimonious and effective test to screen for neurocognitive
impairment in the context of elevated cardiovascular risk in an ambulatory primary care
environment.
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Chapter 1
Introduction
1.1 Alzheimer’s Disease
Dementia is an ever-growing world-wide public health problem. From 2000 to
2019 the rate of death from Alzheimer’s disease (AD), probably the most well-known
dementia subtype, has experienced a 145% increase [1]. In 2021, the United States alone
spent approximately $355 billion in healthcare costs caring for AD and other dementias
[1]. This number includes the money spent to care for patients and the many hours that
family members set aside to care for their loved ones. By 2050, this number could rise to
over a trillion US dollars [1]. As the number of dementia cases rise, so too will the stress
on caregivers, medical professionals, and family members of those affected.
1.2 Mild Cognitive Impairment
Mild cognitive impairment (MCI) is characterized as a prodromal or transitional
state where individuals present with reduced performance on selected neuropsychological
tests and may go on to develop a dementia [2]. Early detection of MCI makes it possible
to slow the onset of dementia with lifestyle changes such as regular exercise and
improved nutritional choices. It is also well understood that when a disease modifying
agent becomes available to treat dementia such as AD, early diagnosis and the
identification of neurocognitive decline such as MCI will be critical for effective
treatment. Much of the prior research on MCI has focused on predicting conversion to
Alzheimer’s disease (AD). A variety of biomarkers including reduced medial temporal
lobe/ hippocampal volume [3-6] and the presence of Aβ40 and Aβ42 proteins in plasma
1

and cerebral spinal fluid [7-9] have proven useful in targeting individuals at increased
risk for conversion to dementia. Some researchers associate MCI with an almost
automatic conversion to AD [10]; however, research suggests that not all patients
classified with MCI go on to develop AD. Some MCI patients demonstrate different
outcomes including the development of non-AD dementia [11].
1.3 Mild Cognitive Impairment: Subtypes
Recent research now suggests the presence of several MCI subtypes [12]. Indeed,
Petersen [13, 14] describes distinct MCI groups including single-domain amnesic MCI
(aMCI) where impaired performance on tests of declarative memory dominates the
clinical picture; single-domain non-memory MCI where patients present with isolated
impairment in some non-memory domain of neuropsychological functioning such as
executive control or language; and multi-domain MCI where several domains of
neuropsychological functioning may be compromised. Using person-centered statistical
techniques, Delano-Wood et al., [15] and Libon et al., [16] have provided evidence for
the existence of multiple MCI groups. In their research, neuropsychological test
performance obtained from groups of memory clinic MCI patients was subjected to
cluster analysis. In both studies three distinct groups emerged – a relatively pure memory
group; patients with impaired performance on tests of executive control and processing
speed; and a mixed memory/ language group. In a world with an increasingly aging
population, identifying distinct prodromal dementia states is critically important and may
constitute one of the most effective tools currently available to identify, predict, and
ultimately treat dementia.
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1.4 Mild Cognitive Impairment and Vascular Risk
Additional evidence for the prevalence and prognosis of MCI subtypes comes
from several large, community-based population studies. For example, Lopez and
colleagues [17, 18] found a higher prevalence of multi-domain MCI compared with
aMCI. Despite its lower prevalence rate, conversion studies suggest that individuals with
aMCI were almost twice as likely to convert to dementia within 2.5 years compared with
individuals diagnosed with other non-amnesic forms of MCI [19]. In another study
examining dementia conversion, most amnesic and dysexecutive MCI patients were
ultimately diagnosed with either AD or subcortical vascular dementia, respectively [20].
In this research the single-domain dysexecutive MCI group presented with more vascular
co-morbidities and signs of vascular disease on T2-weighted MRI studies. In fact,
increased stroke risk factors such as hypertension and diabetes in individuals with MCI
were associated with greater white matter alterations and degraded white matter integrity
as measured by diffusion tensor MRI [15]. Finally, Busse et al., [21] found that an initial
diagnosis of aMCI was almost inevitably associated with a pathological diagnosis of AD
at autopsy. By contrast, less pathological specificity was associated with individuals who
were initially characterized as presenting with single domain, non-memory MCI or multidomain MCI. In sum, the accumulated research suggests that MCI is a very complex and
highly nuanced clinical phenomenon with emerging evidence for the co-morbid effect of
cardiovascular risk factors [22].
1.5 Executive Control and Working Memory
Dysexecutive impairment is one of the key neuropsychological features
associated with MCI [23]. Executive control is best understood as describing a wide
3

range of higher-order neurocognitive behaviors that allow individuals to regulate and
control their behavior to accomplish a task. Executive control allows one to complete
everyday tasks like work duties, what clothes to wear, what foods to eat, and choosing the
best time to go to bed. With executive control comes working memory, characterized by
the ability to mentally maintain and manipulate information for the purpose of
completing a task. Remembering a phone number is a good example of working
memory. Working memory is effectively our short-term memory that we use to complete
tasks in our everyday life.
One test paradigm commonly used to measure executive abilities is the Digit Span
Test – a traditional subtest in the Wechsler corpus of intelligence tests [24, 25]. The
Wechsler version of the digit span test presents two trials of numbers to repeat with
increasing span length. The test proceeds until the individual fails both trials within any
single span length. Digit span forward provides a measure of auditory span or the
number of bits of information that can be held in mind regardless of whether the
completed response is correct. Digit span backward provides a measure of working
memory or the capacity for mental manipulation [26]. Each trial is scored as either
correct or incorrect.
Lamar and colleagues [27, 28] described data obtained using the Backwards
Digital Span Test (BDST). This test is analogous to the commonly used Wechsler Digit
Span Backwards subtest. However, there are some important differences. First, blocks
of 7 trials of 3, 4, 5-span are administered. Second, there is no discontinuation as all test
trials are administered. Third, rather than scoring each trial as correct or incorrect, Lamar
and colleagues [27, 28] calculated ANY order and SERIAL order recall. ANY order
4

recall is scored by awarding a point for each correct response regardless of whether the
order is correct (e.g., 48972 – "27894”= 5/5 or 100% correct). SERIAL recall is scored
by awarding a point only when responses are recalled in their exact serial order position
(e.g., 48972 – "27894”= 3/5 or 60% correct). In prior research Lamar and colleagues [27,
28] found that patients with dementia associated with MRI subcortical vascular disease
presented with worse SERIAL versus ANY order recall. Worse SERIAL order recall has
also been found in memory clinic patients when patients with single domain,
dysexecutive MCI were compared to other MCI groups [16]. Lamar and colleagues [28]
also observed worse SERIAL recall in relation to greater left- sided MRI white matter
alterations (i.e., leukoaraiosis, LA). There was no correlation between ANY ORDER
performance and LA [28] suggesting that LA does not interfere with immediate digit
recall but does interfere with temporal re-ordering of digits.
Emrani and colleagues [29] analyzed BDST SERIAL order performance in
memory clinic patients. Patients were classified into three groups – amnestic MCI
(aMCI), combined mixed/dysexecutive MCI (mixed/dys-MCI), and cognitively normal
(CN). The results showed that the mixed/dys-MCI group scored lower than non-MCI
patients for serial positions 3, 4 and 5. The mixed/dys-MCI group also produced a greater
number of transposition errors, omissions, and preservations than other groups. This data
suggests that assessing mental performance through SERIAL order using the BDST can
dissociate between MCI subtypes.
Recently, Emrani et al. [30] considered latencies produced within correct trails of
the BDST by individuals with MCI (N = 22) and without MCI (N = 36). Their analyses
revealed that non-MCI patients produced slower latencies in positions 2 and 4 in the 55

span BDST. By contrast, MCI patients were slower in their position 3 response, which
suggests that the allocation of time to bring this task to fruition was different for those
patients. Thus, intra-component latencies within a response can provide valuable added
information for MCI screening.
1.6 Significance of the Current Research
Current neuropsychological assessment relies on traditional pen-and-paper tests.
However, recent research has demonstrated the potential for the early identification of
emerging neurodegenerative disease through the use of digital neuropsychological
assessment platforms [30-32]. Using digital assessment technology, we can now collect
time- based data such as intra-component latencies (delays between responses). With
digital technology, test results can now be objectively obtained and scored using the same
criteria used in the pen-and-paper tests. Digital assessment technology can collect a
patient’s responses using voice recognition and/ or touch screen technology. All data
collected using digital technology are time stamped allowing us to know when and where
decisions were made within the context of the total time necessary to complete a task. By
extending previous research described by Emrani and colleagues [29-32] using digital
assessment tools, we can undertake research to collect data previously unobtainable.
In the current research, middle-aged participants were recruited from an
ambulatory primary medical practice. Cardiovascular risks such as treatment for
hypertension, diabetes, elevated cholesterol, and cardiac illness (e.g., MI, CAD, etc.)
were coded. In the current research a digitally administered pointing span test, the
Philadelphia Pointing Span Test (PPST), was deployed. The PPST is designed by Dr.
Ganesh R. Baliga and Dr. David J. Libon and modeled after the Backward Digit Span
6

Test (BDST) [30]. The goals of the current research are 2-fold. First, the concurrent
validity of the PPST as a measure of executive abilities will be investigated. Our first
hypothesis is that PPST executive indices measuring both auditory span (ANY ORDER
recall) and mental manipulation (SERIAL ORDER recall) will be related to other
neuropsychological tests that assess executive abilities. Another goal of the current
research is to assess how well the PPST can screen for neuropsychological difficulties in
the context of cardiovascular risk. Our second hypothesis is that selected PPST latency
measures will be associated with greater cardiovascular risk.

7

Chapter 2
Digital Assessment
2.1 Philadelphia Pointing Span Test
As noted above, digital neuropsychological assessment was conducted using the
Philadelphia Pointing Span Test (PPST). The test was administered using an iOS app
running on an iPad. The PPST is similar to another well-known neurocognitive test –
The Corsi Block Tapping Test [33]. This test is designed to assess visuospatial working
memory and is commonly used with children, adults, and those with neuropsychological
disabilities [34].
The PPST was constructed based on the Corsi Block Tapping Test as described
above as well as BDST. The test contained 5 trials of 3, 4, and 5- span test trials. As
with the BDST, all PPST test trials are administered with no discontinuation. The
digitally administered PPST contains two subtests – (1) a number only test condition, and
(2) a combined numbers/letters test condition. In the numbers only test condition, all
trials consisted of a series of non-repeating Arabic numbers. In this portion of the test,
participants heard a series of numbers from the iPad and were instructed to touch the
answer key ordering their response from the lowest number to the highest number (i.e.,
3729 – “2379”). In the combined numbers/letters test condition, participants heard a
series of non-repeating numbers and letters and were instructed to first touch numbers
from lowest to highest followed by letters in alphabetical order (i.e., 5T3J – “35JT”).
All responses were obtained using touch screen technology. After the stimulus
was delivered participants tapped numbers or letters contained within circles on the
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answer key. Each time a response was made the corresponding button tracked how long
the response took from the time the iPad administered the auditory test trial. The number
or letter inside the button was then highlighted for a quarter of a second, indicating the
selection. Within each trial, the participant must wait until the entire string of digits or
combined digits and letters was spoken before a response can be initiated. Selections
cannot be repeated on the same button in a single trial screen.
In order to have the iPad read out the digit span to the patient, we implemented
Apple’s own text-to-speech synthesizer with the list of stimuli. There are many benefits
to this as opposed to recording sound files. For one, the spoken stimuli can be easily
changed by adjusting the test’s corresponding JSON file. We can also change the voice
and accent just as one can change Siri’s voice settings on an Apple device. We can even
adjust the speech rate and pitch of the voice. Finally, our approach enables us to leverage
the culture-neutral nature of the PPST by easily changing the language of administration.
2.2 iPad Application
Our iPad application is programmed with other neuropsychological tests allowing
practitioners to switch between tests within the main menu. Before starting the test, a
unique patient ID is assigned along with any notes the practitioner wants to include.
There are settings on the main menu allowing for different test parameters. Each test is
defined by a unique JSON file which can be changed on-the-fly, allowing for quick and
easy changes. For instance, if different digits need to be read out in PPST, a simple
change to the JSON file in the correct position will suffice. No other changes are
necessary. This open system allowed us to build and edit tests as necessary.
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After a test is completed, the results are stored into a JSON file and sent to our
database. From there, researchers can open our web client, enter their credentials and
password, and then access the formatted spreadsheets. The spreadsheets are formatted
using Python language library OpenPyxl [35] and pre-formatted spreadsheet templates.
Using OpenPyxl we can have specific cells within a spreadsheet use Excel functions that
access spreadsheet columns and rows of our choice. These spreadsheets are then exported
through our AWS Lambda-based backend. The AWS Lambda service [36] enables
software developers to run programs in AWS’ cloud without maintaining a dedicated
server. Deployment to AWS Lambda was handled using Python language serverless
framework Chalice [37]. For our purposes it made sense to access our web client and
spreadsheets only when requested. These design choices have allowed our research to
remain lean and adjustable.
2.3 Virtual Reality Application
We are also interested in exploring the value that other digital measurements
might add to neuropsychological testing. In addition to collecting time-based parameters
such as response latencies, a small group of VR headsets are also capable of tracking eye
position (eye tracking) and providing biometric data such as pulse, thereby supporting the
collection of a richer dataset as compared to our iPad-based tests. We implemented
several cognitive tests, including Cancellation and Angle Matching (see Appendix for
descriptions), in a desktop application environment that uses virtual reality (VR).
COVID-19 dictated social distancing and remote work constraints have delayed data
collection on our VR-based tests. The results and discussion of forthcoming chapters
pertain to the iPad-based tests. This section describes our VR work to date.
10

We assumed that VR assessments would be tolerated by patients from a younger
age group. During prototyping, elderly family members were asked to help test the VR
application and we discovered that VR-based testing was well-tolerated with only minor
adjustments to ensure comfort. There are two straps on the headset that need to be
adjusted to ensure it rests comfortably on the patient’s head. Patients are seated and
stationary during testing so there was no issue of nausea or discomfort. For patients with
glasses, we asked that they remove them in order to prevent damage to the glasses as well
as the lenses on the VR headset.
2.3.1 Hardware Acquisition
The first step in the VR research was to identify a research-grade VR headset that
includes biometric tracking capabilities into one package and was also available off the
shelf. At the time, the options that satisfied these criteria were extremely limited.
Thankfully, Hewlett Packard (HP) launched the Reverb G2: Omnicept Edition
VR headset [38] in spring 2021. The base version of this product is meant simply for VR
gaming and offers high resolution lenses and speakers to deliver a high-quality immersive
and comfortable VR experience. The upgraded Omnicept version augments the base
version with a variety of biometric sensors that measure muscle movement, eye gaze,
pupil size, and pulse (heart rate) all in one package. The eye-tracking sensors are
provided by Tobii AB [39], leading innovators in eye tracking technology. The next step
after acquiring the proper hardware was to design and implement an application that can
run our cognitive tests in a VR environment.
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2.3.2 VR Implementation
With this complete package of sensors and a computer capable of running the
headset smoothly, there is the potential for conducting neuropsychological tests that
capture more information than the comparable iPad assessments. Over six months of
development time was dedicated exploring our options with VR testing until we
ultimately decided to put it aside and focused our research efforts on iPad assessment.
This was time spent learning how to use Unity, and designing a test that would work
within the limits of the hardware and software in our stack. For this reason, it is important
that this is mentioned as many efforts were made to make this research possible.
Some challenges we faced when designing the VR tests are discussed in Chapter
5 (Conclusions and Future Work) and within the Appendix. In the following chapters, we
will detail the assessments conducted on our iPad application and analyze and interpret
the data that was collected.
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Chapter 3
Methods
3.1 Participants
The current research recruited 51 patients from Rowan University, Department of
Family Practice. These participants were recruited for the current study as part of their
routine medical care. Inclusion/ exclusion criteria included (1) English is the
participants’ first language, (2) major medical/neurological illness, such as cancer or
epilepsy, that might be expected to alter cognitive abilities, were absent; and (3) no
dementia will be present. Demographics are listed in Table 1. The sample was middleaged (52.37+ 14.27 years); relatively well educated (14.24+ 1.68 years); and the majority
of participants were female (62.70%). Gross neurocognitive abilities were assessed with
the Montreal Cognitive Assessment (MoCA) [40, 41]. Scores on this test range from 0 –
30. Mean MoCA performance was 24.42+ 2.66 (Table 1).

Table 1
Demographic and MoCA Test Performance
(N = 51)

Age

Education
years)

MoCA
Score

Range

56

6

11

Minimum

23

12

18

Maximum

79

18

29

Mean

52.37

14.24

24.41

Standard
Deviation

14.27

1.68

2.66
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3.2 Cardiovascular Risks
Cardiovascular risks (CVR) were coded including treatment for elevated
cholesterol, diabetes, heart disease, and hypertension. Each CVR was scored as 0 when
not present, 1 when present and treatment is ongoing, and 2 when present and no
treatment is currently provided. Cardiovascular risks were summed to create a CVR
index (range 0 – 4). Participants’ systolic and diastolic blood pressure and A1C value
was coded when available. The A1C test, a popular test used to diagnose prediabetes and
diabetes, measures the average blood sugar level in a patient over the past three months.
3.3 Statistical Analysis
Statistical analysis was performed using IBM Statistical Product and Service
Solutions (SPSS) [42].
3.3.1 PPST ANY and SERIAL ORDER and MoCA Test Performance
MoCA test performance was first analyzed using principal component analysis
(PCA) to extract indices assessing executive, language, and verbal memory abilities.
Relations between MoCA PCA derived indices and PPST ANY order and SERIAL order
recall were assessed with Pearson correlational analyses. Correlational analyses were
also used to assess relations between PPST ANY order and SERIAL order recall and the
CVR index defined in Section 3.2.
3.3.2 PPST Latency Measures
The latency to generate individual PPST responses from both test conditions was
correlated with PCA derived MoCA indices assessing executive, language, and verbal
memory abilities. Separate regression analyses were conducted to assess the relation
14

between the CVR index and latencies to generate individual responses on the PPST
numbers only and the combined number/letter test conditions. For these analyses, age
was entered into the first block. Latencies for 3, 4, and 5-span responses were entered
into the second block, respectively.
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Chapter 4
Results
4.1 MoCA Principal Component Analysis
Table 2 lists the MoCA parameters subjected to PCA using varimax rotation.
This analysis resulted in a 3–factor solution accounting for 68.31 percent of variance
(Table 2). Factor 1 (executive control) contained three variables - time to completion for
the MoCA Trail Test– Part B, time to completion for subtracting serial 7s, and MoCA
clock drawing errors. Factor 2 (language) was related to performance on MoCA Naming
and Similarities tests. Finally, factor 3 (memory) was related to verbal memory test
performance as measured by the MoCA cued recall and recognition tests.

Table 2
MoCA Principal Component Analysis

Trail Making Test–
(time to completion)
Subtracting Serial 7s
(time to completion)
Clock Drawing
Errors
Naming Test
Performance
Similarities Test
Performance
Delayed Cued
Recall
Delayed
Recognition
Variance

Factor 1

Factor 2

Factor 3

0.761

-0.337

-0.136

0.719

-0.483

-0.087

-0.740

-0.318

0.169

-0.006

0.821

0.042

-0.170

0.615

0.226

-0.004

0.132

0.890

-0.322

0.112

0.760

37.44

16.16

14.69
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4.2 PPST ANY and SERIAL ORDER and MoCA Test Performance
Descriptive statistics for PPST ANY and SERIAL ORDER recall can be found in
Table 3 below, which shows that the PPST was well tolerated by the patients in our
sample.

Table 3
PPST Percent ANY and SERIAL ORDER Correct
PPST Number Test Condition
mean
PPST 3-span ANY ORDER
99.86
PPST 3-span SERIAL ORDER
99.31
PPST 4-span ANY ORDER
99.90
PPST 4-span SERIAL ORDER
98.96
PPST 5-span ANY ORDER
97.62
PPST 5-span SERIAL ORDER
90.64
PPST Number/ Letter Test Condition
mean
PPST 3-span ANY ORDER
99.17
PPST 3-span SERIAL ORDER
96.67
PPST 4-span ANY ORDER
97.08
PPST 4-span SERIAL ORDER
91.69
PPST 5-span ANY ORDER
87.75
PPST 5-span SERIAL ORDER
74.88

standard deviation
0.96
2.83
0.72
5.26
4.31
13.17
standard deviation
2.96
8.91
4.82
13.76
9.92
17.85

The Pearson Product Moment Correlation (i.e., ‘r’) is a bivariate statistical
analysis that measures the relation between two phenomena, namely, (1) the strength of
the association between two variables, and, (2) the direction of that relationship. The
Pearson correlation coefficient ranges between +1.00 and -1.00. A value of +1.00 or 1.00 suggests a perfect relationship. As the correlation coefficient values moves toward
zero, the relationship between the two variables grows weaker. The direction of the
17

relationship is indicated by the sign of the coefficient. A positive relationship suggests
that as value of one variable increase, the value of the second variable also increases. A
negative relationship suggests that as the value of one variable increases, the value of the
second variable decreases. In the neuropsychology field, a correlation value between
0.3-0.5 is considered promising when attempting to establish concurrent validity
between an established assessment and an untested assessment.
The p-value obtained with Pearson’s correlation analysis describes the
significance of the correlation in as far as how well it rejects the null hypothesis, meaning
that there is no relationship between the two variables. Informally stated, a sufficiently
low p-value means that the null hypothesis can be rejected. In our research, we set our pvalue threshold at 0.05, so any values below this threshold have a very low probability of
supporting the null hypothesis. Correlations with a p-value below 0.05 are statistically
significant and any values below 0.01 are even more significant.
In the number test condition, Pearson correlation analyses found a correlation
between MoCA PCA derived executive index and PPST 3-span SERIAL ORDER recall
(r= -0.348; p< 0.016); PPST 4-span recall (r= -0.376, p< 0.009), and 5-span SERIAL
ORDER recall (r= -0.405, p< 0.005), where slower time to completion and greater
number of clock drawing errors were associated with worse PPST SERIAL ORDER
recall.
For the number/letter test condition, the MoCA PCA derived executive index
slower time to completion and a greater number of clock drawing errors correlated with
reduced PPST 4-span ANY ORDER (r= -0.309, p< 0.034); 4-span SERIAL ORDER
recall (r= -0.366, p< 0.012); and 5-span SERIAL recall (r= -0.288, p< 0.049).
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4.3 PPST ANY and SERIAL ORDER Recall and Cardiovascular Risk
Analyses examining blood pressure and cholesterol were not significant.
Additionally, no significant results were found for the number test condition. However,
for the combined number/letter test condition, elevated A1C was correlated with reduced
PPST 3-span ANY ORDER recall (r= -0.362, p< 0.046) and reduced PPST 4-span ANY
ORDER recall (r= -0.392, p< 0.029). For the CVR index, greater evidence for
cardiovascular risk was associated with reduced PPST 3-span ANY ORDER (r= -0.531,
p< 0.001) and PPST 5-span ANY ORDER recall (r= -0.356, p< 0.018).
4.4 PPST Latency Data and Neuropsychological Performance
The latency to generate all responses for the PPST number and combined number/
letter test conditions are contained in Tables 4-6. Correlation between MoCA PCA
derived neuropsychological indices and 3-span and 4-span latencies in the 3 and 4-span
trials blocks were not significant. Nonetheless, in the 5-span number test condition,
longer or slower 3rd and 5th response latency was associated with better performance on
the MoCA PCA derived memory index (r= 0.314, p< 0.038; r= 0.401, p< 0.007,
respectively). None of these analyses were significant for the combined number/letter
test condition.
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Table 4
PPST 3-Span Latency (Mean & Standard Deviations)
PPST Number Test Condition

Mean
Std. Deviation

PPST 3- span 1st
latency
2.16 secs
0.75

PPST 3- span 2nd
latency
0.86 secs
0.62

PPST 3- span 3rd
latency
0.66 secs
0.27

PPST Number/ Letter Test Condition

Mean
Std. Deviation

PPST 3-span 1st
latency
2.55 secs
1.33

PPST 3-span 2nd
latency
1.21 secs
0.57

PPST 3-span 3rd
latency
0.75 secs
0.28

Table 5
PPST 4-Span Latency (Mean & Standard Deviations)
PPST Number Test Condition

Mean
Std. Deviation

PPST 4span 1st
latency
1.84 secs
1.01

PPST 4-span
2nd latency
2.72 secs
1.28

PPST 4-span
3rd latency
3.73 secs
1.73

PPST 4-span
4th latency
4.36 secs
1.97

PPST 4-span
2nd latency

PPST 4-span
3rd latency

PPST 4-span
4th latency

0.87 secs
0.41

2.20 secs
0.86

0.91 secs
1.69

PPST Number/ Letter Test Condition

Mean
Std. Deviation

PPST 4span 1st
latency
2.50 secs
0.94
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Table 6
PPST 5-Span Latency (Mean & Standard Deviations)
PPST Number Test Condition

Mean
Std.
Deviation

PPST 5span 1st
latency
2.13 secs

PPST 5span 2nd
latency
0.99 secs

PPST 5span 3rd
latency
1.72 secs

PPST 5span 4th
latency
1.30 secs

PPST 5-span
5th latency

1.28

0.54

1.37

0.99

0.34

0.56 secs

PPST Number/ Letter Test Condition
Mean
Std.
Deviation

2.99 secs

0.85 secs

2.44 secs

1.92 secs

0.96 secs

1.61

0.55

2.91

1.23

1.38

4.5 PPST Latency and Cardiovascular Risk
Tables 4-6 above show means and standard deviation for latencies obtained in
patient trials for PPST 3-span, 4-span and 5-span (number and number/letter conditions)
respectively. To explore the interesting patterns that were observed, a series of regression
analyses were conducted examining relationships between the CVR index and PPST
latencies. In these analyses, age was entered in block 1 followed by latencies within each
trial block entered in block 2. Analyses looking at 3, 4, and 5- span latencies in the
numbers only test condition were not significant. The analyses looking at 3 and 4- span
latencies in the combined number/letter test condition were also not significant.
However, the analysis of the 5-span combined number/letter test condition was
significant (R= 0.594, R2= 0.353, df= 5/ 30, F= 2.74, p< 0.037). Only the latency for the
fifth response entered the final model (beta= 0.519, p< 0.003), suggesting that for the
PPST, slower latency is associated with increasing cardiovascular risk.
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Chapter 5
Conclusions and Future Work
5.1 Research Accomplishments
The purpose of the current research was to demonstrate the efficacy of using a
digital platform to administer and score neuropsychological tests. As found in previous
research [31, 32] and in the present study, assessing neuropsychological abilities using
digital technology permits the collection of highly nuanced data that previously has not
been obtainable.
In the current research, the PPST was administered to a group of patients drawn
from an ambulatory family medical practice. Patients were not suspected of having any
neurocognitive issues and were assessed as part of their routine medical care. Along with
the PPST, patients were administered the MoCA. The current research tested two
hypotheses. Our first hypothesis was that PPST indices measuring auditory span (ANY
ORDER recall) and mental manipulation (SERIAL ORDER recall) will be related to
other neuropsychological indices that assess executive abilities. Our second hypothesis
was to assess how well the PPST can screen for neuropsychological difficulties in the
context of elevated cardiovascular risk.
In the current research, selected MoCA test parameters were analyzed using a
principal component analysis. This analysis resulted in the compilation of three
neuropsychological indices measuring executive abilities, language, and verbal episodic
memory, respectively. Consistent with our first hypothesis, PPST SERIAL ORDER
recall was statistically related to the MoCA PCA executive index. As described above,
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on the PPST numbers test condition, correlational analyses found reduced MoCA
executive test performance associated with reduced PPST 3, 4, and 5-span SERIAL
ORDER recall. When the PPST combined number/letter test condition was analyzed,
reduced MoCA executive abilities was found in relation to reduced PPST 4-span ANY
ORDER, as well as 4 and 5-span SERIAL ORDER recall.
These data are consistent with previous research described by Lamar et al., [27,
28] and Libon et al., [26]. In these studies, memory clinic patients with dementia and
MCI were studied. Analogous ANY and SERIAL recall indices correlated with other
measures of executive abilities as well as posterior and anterior MRI white matter
alterations. Moreover, in previous research, Emrani et al., [29] demonstrated how
SERIAL ORDER scoring can more effectively differentiate mixed/dys-MCI patients
from non-MCI and aMCI patients. Taken as a whole, the current findings along with past
research provide support for the concurrent validity for the PPST as means to assess
executive abilities.
Past research has found that cardiovascular risk such as hypertension, cholesterol,
and diabetes are highly associated with reduced performance on neuropsychological tests.
De Anda-Duran [43] studied a group of community dwelling research volunteers from
the Bogalusa Heart Study. These researchers found that chronic cardiovascular risk, such
as diabetes and hypertension, were highly associated with reduced performance on
neuropsychological tests assessing executive and information processing speed abilities,
as well as greater carotid stenosis. Consistent with this research and our second
hypothesis, PPST test performance was also associated with greater cardiovascular risk.
Elevated A1C was associated with reduced 3 and 4-span ANY ORDER recall. A greater
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score on the cardiovascular risk index was also associated with reduced 3-span and 5span ANY ORDER recall. When individual latencies were examined from correct PPST
5-span test trials in number test condition, greater cardiovascular risk was associated with
slower latency to generate the second response. Greater cardiovascular risk was also
associated with slower latency to generate the fifth response in the combined
number/letter test condition.
5.2 Lessons and Challenges
Multiple applications were prototyped in order to test the limits of
neuropsychological assessments on digital platforms. Between the VR and iOS platforms,
there were major differences that led to the use of some tests and the rejection of others.
For example: the Cancellation task was difficult for VR users as the eye tracking sensors
are not precise enough to differentiate between two closely-placed objects. However, this
test was well-tolerated on the iPad application as replication of this test was nearly
identical to the original pen-and-paper version. The most effective test for VR and eye
tracking was the Angle Matching test which has 9 oblique lines on the VR display. It was
simple enough for eye tracking while still maintaining a level of difficulty.
While there are others to mention, more implementation challenges can be found
in the Appendix. Due to my own lack of experience in 3D game engines, several months
were spent on learning the technology that would power our digital assessments on our
VR platform. Many challenges resulted from technical considerations of whether a
feature was possible to implement on the hardware, and also whether that feature would
be well-tolerated by the patients. A test that is too easy will not assess anything about the
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patient, and a test that is too difficult will not be effective for data collection. There had
to be a balance of difficulty in order for effective data collection.
Every test we implemented went through several iterations before reaching its
finalized version. A test’s user interface must be intuitive for both patient and test
administrator. For instance, one iteration of the PPST focused on allowing the
backtracking of trials in situations where the test administrator felt a trial should be readministered. In this case, our data collection would only track the data of the most recent
trial response. Multiple changes also had to be made to the voice synthesizing used in our
application. Patient feedback was used to arrive at a synthesized voice that was welltolerated.
5.3 Conclusion
A major strength of the current research is the engineering of a new digitally
administered test able to assess executive abilities and the use of innovative technology to
obtain latency data that was previously unobtainable. Several weaknesses of our research
must be acknowledged. First, our sample was modest, and the number of cardiovascular
risks were also modest. Additional research with a larger sample is necessary to replicate
the data reported above. Second, to validate the relationship between PPST and
neuropsychological test performance, PPST ANY and SERIAL recall, and the latency
measures should be validated against a comprehensive neuropsychological protocol.
Despite these weaknesses, the data described suggest that the PPST could be a
parsimonious and effective test to screen for neurocognitive impairment in the context of
elevated cardiovascular risk in an ambulatory primary care environment. In summary,
we augmented classical neuropsychology with digital administration. We successfully
25

built a digital test using the PPST and we were able to provide evidence for how well it
can assess executive function and CV risk. Additionally, we explored the limits of
neuropsychological assessments in a VR setting and left a solid foundation for future
research.
5.4 Future Work
This research is not complete in the sense that additional testing and evaluation
needs to be performed to ensure that our assessments are in line with their traditional
counterparts. Our limited population leaves an opportunity for more data collection for a
wider population.
There is also the opportunity for data collection with our VR assessments.
Constraints related to COVID-19 restrictions and delays caused by supply disruptions
forced us to reel back some of our original research goals. The exploration of VR-based
neuropsychological assessments is likely to continue. Based on our limited experience
with building VR-based assessments, we posit that that these assessments are promising
due to the rich amount of data that can be collected. In the future, we anticipate that more
Computer Science researchers will be intrigued by the potential of this research and what
it could mean for the well-being of future generations.
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Appendix
Challenges of Implementation
Apple iPad and iOS Programming
In their prior work on digital neuropsychological assessment, Drs. Baliga and
Libon had chosen the iPad as the test administration platform. Our work considered two
possible choices for software platform. The first choice was a cross-platform framework
such as Facebook’s React Native or Google’s Flutter. The most important advantage of
this approach was that it could lead to an app that works both on Android and iOS
platforms. The second choice was to use Apple’s Xcode and the Swift programming
language to create a native iOS app. We adopted the second approach primarily because
it allows for very fine-tuned programs and access to Apple’s libraries that would not have
been easily available had we adopted the first approach. For example, we would not be
able to directly access information from the Apple Pencil. This information was useful in
some of the tests that were implemented, where we used pressure data from the Apple
Pencil to understand a patient’s motor input.
Xcode uses a storyboard to graphically lay out how different views (or menus)
flow from one to the next. There is no way to programmatically construct new views
without having to do something in the GUI of Xcode. Thus, each view has to have code
specific to how the app will interact in that view and you have to, by hand, lay out the
flow of the app. This can quickly get out of hand depending on how many cognitive tests
are included.
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In many cases, there are times where the documentation from Apple is sparse. In
these situations, I found myself consulting forums such StackOverflow [44] where such
problems and solutions are discussed by other app developers. For example, every time a
“touch” is detected on the screen, a new Touch object is created. However, we have to
look into the coalesced touches for each patient stimulus selection in order to obtain the
full gamut of data that was collected in that input. By doing this, we can get an accurate
measure of the pressure, azimuth angle, and altitude applied to the Apple Pencil when it
is used in the test. This detail was not readily apparent in Apple’s documentation at the
time of development.
Cancellation Test Challenges
2D collision detection is another tricky feat in Swift to accomplish. This was
relevant for the Cancellation and Angle Matching tests. The Cancellation test, designed
by Dr. Baliga and Dr. Libon, features three test conditions (presented in 3 screens),
namely, a letter condition, a symbol condition and a symbol-letter combined condition. In
the letter condition, the patient is provided with a screen comprising several hundred
different letters located at different positions within the screen. The patient has to use the
Apple Pencil to circle all occurrences of a specified target letter. In our implementation of
cancellation this test, we need to be able to tell if the circle drawn by a patient is
surrounding an object on the screen. This is easier with letters and symbols since we can
just draw a CGRect around the element and adjust the size and dimensions as we please.
Then we can easily check if a CGRect is colliding with another.
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Angle Matching Test Challenges
The Angle Matching test is a visual test designed by Dr. Baliga and Dr. Libon that
tests for a patient’s ability to assess orientation of lines presented in a two-dimensional
space. A stimulus in the Angle Matching test contains one target line and some candidate
lines. Exactly one candidate line, i.e., the correct answer, has the same orientation as the
target line and the rest of the candidate lines are foils. The patient’s task is to select the
correct answer. We implemented this test on the iPad and using Virtual Reality (see
below). In the iPad implementation of this test, it is not possible to use the CGRect object
functionality to detect which line was selected. This is because CGRect objects are bound
to the coordinate axes. Rotating the graphical context will only change how the CGRect
object appears but it does not change the space it occupies. A better solution to this
problem was to check if the bounding box of the drawn path intersects with the bounding
box of the angle. This prevents the bounding boxes of our angles from being too large in
order to account for their full width and length, and allows patients to mark an angle
simply by drawing a line through it rather than having to draw a circle around the entire
line. Thus, we have a more precise method of detecting collisions between the Apple
Pencil path and the angled line’s bounding box.
In our iPad application, we desired a modular and easily adjustable system to
display tests and track data. Very early in development, we agreed that all tests and trials
should be dictated by a JSON file that includes all the parameters. This way, all visible
stimuli can be adjusted without having to change any code, just the JSON file that
controls the test.
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Unity
Unity [45] is a 3D game engine that has seen use in a multitude of science
projects from industry to educational research. Unity was chosen as our 3D engine
because of its ease of use, which advertises a gentler learning curve as opposed to Epic
Games’ Unreal engine [46]. These two 3D engines are known as industry standards and
their use can be seen across a wide range of media and technology. While both 3D
engines are capable for this project and will work with HP’s headset and biometric
sensors, Unity allows the use of C# scripts which are less time-consuming to write as
opposed to Unreal’s use of C++ for scripting. Additionally, Unity’s documentation and
community proved to be helpful in a variety of design challenges.
There are a multitude of VR frameworks that interface with Unity’s XR (extended
reality) layer, including Windows Mixed Reality (WMR), Valve Software’s OpenVR
[47], and OpenXR [48] which uses a compatibility layer to work with the VR APIs listed
as well as a few not listed. For the purposes of this test, I decided on the OpenXR loader
since this will allow for new VR headsets and eye tracking protocols to be implemented
without changing the VR display layer. This will also allow for additional input devices.
This seems to be where the Unity community is moving towards, as more and more VR
devices with new capabilities become available.
Handling User Displacement
In some versions of tests, I use a script to adjust the view of the patient. This is
necessary when a patient is not looking directly forward at the test stimuli or for whatever
reason is displaced while in the VR environment. To achieve this, I apply an offset to the
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VR camera, and adjust its rotation if the view is too far away from the test stimuli. The
animation is smooth and is not uncomfortable or nauseating for the user.
Adjusting to the VR environment
Due to the differences in how space is defined between iPad and Unity, I had to
adjust how the stimuli is displayed in Unity, as our first implementations were on the
iPad. The coordinate systems used in Unity and in the Swift language graphical API are
different. In Swift, UI elements are drawn on the screen using the top left corner as the
origin point. This means that the Y coordinate value increases as you go down. In Unity,
this Y axis is flipped so the origin point is on the floor. In order to draw angled lines for
our Angle Matching test, I flipped the Canvas object that displays the lines. These lines
are parented to the Canvas object, so by flipping the Canvas, the lines are also flipped.
Thus, the stimuli and JSON file dictating how UI elements are drawn did not have to be
changed at all. Like the iPad application, the JSON files that dictate the structure of the
test can be effortlessly swapped between iPad and Unity applications as long as the test
itself has been implemented.
Early into development, we believed it was important to figure out how to make
UI elements that did not appear for the VR user. I thought it would be helpful for the test
giver to see certain data such as pulse and cognitive load as the test progresses.
Additionally, seeing their progress in identifying the correct stimuli would also be
helpful. It would not make sense for the test taker to see their own pulse as the test is
being done. That would be potentially stressful and does not help the test taker. It makes
more sense to only give this information to the test giver. This can be achieved by
pointing UI elements to the test giver’s monitor, and only pushing what is important to
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the test taker. This separation of UI elements is important so that the test giver can dictate
the parameters of the test while the test taker can wait patiently as they become
acclimated to the VR environment.
Data Collection Challenges
There is no built-in feature in HP’s or Tobii’s libraries that allow you to track
what objects have been hovered and any details tied to that hover (timestamp, what object
was hovered on, etc.) This feature does exist, but requires users to pay over $1.5K for a
research license to Tobii who developed the software. For my own purposes, I decided to
program my own version of this software. This system uses collision objects surrounding
each quadrant of the test screen, allowing us to know if a patient is looking in a certain
area, but not at any stimuli. This system reports the timestamp of the gaze detected,
where this gaze was, and for how long it lasted. We can then differentiate between
regions of the space as well as how long they spent looking at the target angle.
With this solution we can effectively know when and where a patient was looking
and what kind of decisions they were possibly making during that time. This solution also
helps with a few other problems, as a more complex solution might have to know the
user’s head position and rotation to understand exactly where they are looking.
Design Challenges of the Eye Tracking Tests
In these VR versions of cognitive tests, patients must provide input by using an
included controller with the VR headset. By clicking a button on the controller, a
selection can be made on an object that a person is gazing at. This is a departure from the
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way that similar Cancellation and Angle Matching tests are carried out on pencil-andpaper test, where the patient selects a stimulus presented on a page by circling it.
Various cognitive tests were implemented using Unity’s 3D game engine and an
assortment of libraries that seamlessly integrate eye tracking input and biometrics from
HP’s headset. The code needed to acquire real-time eye tracking data was provided by
HP and Tobii and designed to interface with 3D game engines like Unity and Epic
Games’s Unreal engine.
Just like in our iPad tests, the test parameters are determined by parsing a JSON
file that includes information about a trial’s stimuli. Afterwards, 3D objects had to be
designed to react when a user’s eyes look at an object. Once that was put together, I built
a system that would be able to report how long a certain object or area within the virtual
environment was looked at and at what time interval during the trial (as described above).
This is done simply by assigning collision objects to 3D objects. The patient’s eye gaze is
represented by a ray pointing from their eyes. If that ray collides with a 3D collision
object that means it is being looked at. The 3D object can be programmed to visually
react by changing color if desired. The patient’s pulse and pupillometry can also be
recorded for the duration of the test.
After integrating the Cancellation test into our application, we realized that the
eye tracking and gaze detection capabilities of our VR platform are not sufficiently
accurate and precise. This is mainly due to the distance from the VR user to the stimuli.
In Cancellation, there are over 200 stimuli on the screen and thus the stimuli had to be
properly distanced from the viewer. Tobii’s eye tracking sensors model the viewer’s eye
gaze as a cone of vision. Given the number of stimuli on a Cancellation test’s screen and
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the distance to the viewer, that cone of vision does not always contain a single stimulus,
making it impossible for our application to discern which letter is being viewed. In the
VR environment, the Cancellation test can become overwhelming due to the number of
elements on the screen, which led us to abandoning further development of this test
focusing our attention on the Angle Matching test. Our implementation of this test
provides latencies, eye position, and biometrics such as pulse during the entire duration
of each response.

40

